UNSPSC 51263159: Celiprolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C20H33N3O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G1M3398594, chemically known as 3-(3-acetyl-4-(3-((tert-butyl)amino)-2-hydroxypropoxy)phenyl)-1,1-diethyluronium chloride but more generally known as celiprolol hydrochloride, which bears US NIH Compound Identifier 42373. European Medicines Agency schedules Celiprolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01146MIG.

UNSPSC 51263159 Celiprolol hydrochloride is a Commodity code nominally covering a specific beta-blocker pharmaceutical active ingredient, but recent state and local procurement activity shows no solicitations directly matching this drug product. The single relevant recent opportunity posted under this code—Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems—concerns emergency-response medications and harm-reduction equipment unrelated to celiprolol's therapeutic class or clinical use. A second opportunity, the Texas Health and Human Services Commission's RFI HHS0017013 on direct-to-manufacturer prescription programs, addresses pharmacy benefit program structure and contracting rather than procurement of a named pharmaceutical product. The code shows little actionable recent activity aligned with its stated commodity scope.

The geographic spread of identifiable activity is limited to Florida and Texas, with no pattern of repeat buyers or sustained procurement under this specific drug code. State and local health agencies and benefits programs appear to be the primary issuing bodies, but the opportunities present do not demonstrate demand for celiprolol hydrochloride itself. Business development teams pursuing this code should verify whether state formularies, group purchasing organizations, pharmacy benefit managers, or institutional procurement offices have active demand for this ingredient or finished-form products containing it—the recent opportunities do not establish a market signal sufficient to guide pursuit strategy at this time.